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Abstract
Background: Carpal tunnel syndrome is caused by entrapment of the median nerve and results in pain, tingling
and numbness in the wrist and hand. It is a common condition in general practice. Effectiveness of treatment by
intracarpal corticosteroid injection has never been investigated in general practice. The objective of this study was
to determine if corticosteroid injections for carpal tunnel syndrome provided by general practitioners are effective.
Methods: In this study 69 participants with a clinical diagnosis of carpal tunnel syndrome were recruited from 20
general practices. Short-term outcomes were assessed in a randomised, placebo-controlled trial. Long-term results
were assessed in a prospective cohort-study of steroid responders.
Participants were randomised to intracarpal injections of 1 ml triamcinolonacetonide 10 mg/ml (TCA) or 1 ml NaCl
(placebo). Non-responders to NaCl were treated with additional TCA injections. Main outcomes were immediate
treatment success, mean score of the Symptom Severity Scale (SSS) and Functional Status Scale (FSS) of the Boston
carpal tunnel questionnaire, subjective improvement and proportion of participants with recurrences during follow-
up. Duration of follow-up was twelve months.
Results: The TCA-group (36 participants) had better outcomes than the NaCl-group (33 participants) during short-
term assessment for outcome measures treatment response, mean improvement of SSS-score (the mean difference
in change score was 0.637 {95% CI: 0.320, 0.960; p < 0.001}) and FSS-score (the mean difference in change score
was 0.588 {95% CI: 0.232, 0.944; p = 0.002}) and perceived improvement (p = 0.01). The number to treat to achieve
satisfactory partial treatment response or complete resolution of symptoms and signs was 3 (95% CI:1.83, 9.72).
49% of TCA-responders (17/35) had recurrences during follow-up. In the group of TCA-responders without recur-
rences (51%, 18/35) outcomes for SSS-score and FSS-score deteriorated during the follow-up period of 12 months
(resp. p = 0.008 and p = 0.012).
Conclusions: Corticosteroid injections for CTS provided by general practitioners are effective regarding short-term
outcomes when compared to placebo injections. The short-term beneficial treatment effects of steroid injections
deteriorated during the follow-up period of twelve months and half of the cohort of steroid-responders had
recurrences.
Trial registration: Current Controlled Trials ISRCTN53171398
Background
Carpal tunnel syndrome (CTS) is caused by entrapment
of the median nerve at the wrist and symptoms consist
of paresthesias and numbness in the area of median
nerve innervation. Frequently pain in the hand and wrist
is present, sometimes radiating to more proximal areas
of the arm. Most cases are idiopathic, sometimes there
are underlying factors causing compression of the med-
ian nerve (e.g. oedema during pregnancy)[1-3]. The role
of occupational and recreational hand use in causation
remains controversial. The exact role of overuse in the
aetiology of CTS remains unclear, although there is
some evidence that regular and prolonged use of hand-
* Correspondence: raju@dds.nl
Department of General Practice, University Medical Center Groningen,
Groningen, the Netherlands
Peters-Veluthamaningal et al. BMC Family Practice 2010, 11:54
http://www.biomedcentral.com/1471-2296/11/54
© 2010 Peters-Veluthamaningal et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.held vibratory tools and prolonged and highly repetitive
flexion and extension of the wrist increases the risk
[1-3]. In the Netherlands (7.000.000 working people) it
has been estimated that every year 370.000 days of
absence from work result from disability caused by CTS.
This corresponds with 26,5 million euro of costs per
year caused by absence from work due to CTS [2].
CTS is a frequently encountered condition with an
annual incidence rate of 1.8 per 1000 (males 0.9/1000,
females 2.8/1000) in general practice in the Netherlands
and the prevalence rate in the general population is
5.8% (9% for women and 0.6% for men)[4-6]. The aver-
age list size of general practitioners in the Netherlands
is 2350 patients.
There is no golden diagnostic standard for CTS and in
practice guidelines it is advised to establish the diagnosis
using a combination of symptoms, signs and electrophy-
siological testing[2,7].
CTS can be treated with oral analgesics, splinting,
injections with corticosteroids or surgery. A Cochrane
review investigating local corticosteroid injection for
carpal tunnel syndrome showed that steroid injection
provides greater improvement in symptoms one month
after injection than placebo injection, but significant
symptom relief of steroid injection beyond one month
could not be demonstrated[8]. The risk of adverse
events for steroid injection therapy for CTS has been
estimated to be less than 0,1%[9]. In another Cochrane
review addressing efficacy of other non-surgical treat-
ments oral steroids, splinting, ultrasound, yoga and car-
pal bone mobilisation showed to be of short-term
benefit[10]. A third Cochrane review comparing surgical
to non-surgical treatment concluded that surgical treat-
ment of carpal tunnel syndrome relieves symptoms sig-
nificantly better than splinting[11].
In general practice in the Netherlands 25% of patients
with a clinical diagnosis of CTS are referred to neurolo-
gists for further evaluation and treatment[5]. It is not
known what percentage of patients with CTS is treated
conservatively and which operatively.
If corticosteroid-injection provided by general practi-
tioner proves to be effective and safe, it could have
important advantages for individual patients (less wait-
ing-time and the availability of this treatment modality in
the proximity of the patient) and healthcare-system
(treatment in primary care would be more cost-effective).
We therefore decided to conduct a randomised, double
blind, placebo controlled trial to investigate efficacy and
safety of corticosteroid injections provided by their general
practitioner for patients with a clinical diagnosis of CTS.
Methods
This trial is part of a larger study called the Groningen
Hand and Wrist Injection Therapy Trial (HAWITT) in
which efficacy and feasibility of steroid injections for
carpal tunnel syndrome, de Quervain’s tenosynovitis and
trigger finger in primary care was evaluated. In this
report the results for carpal tunnel syndrome are
described.
The trial was approved by the Medical Ethics Com-
mittee of University Medical Centre Groningen (METc
2002/020c).
Setting
Patients were recruited from the practices of 20 general
practitioners in the northern part of the Netherlands.
Patient recruitment and in- and exclusion criteria
Patients presenting to the participating general practi-
tioners with symptoms and signs suggestive of carpal
tunnel syndrome were eligible for inclusion. Exclusion
criteria were thenar atrophy, being less than years of
age, presence of contraindications for corticosteroid
injection (hypersensitivity to corticosteroids, local skin
infection), prior treatment for CTS in the last six
months with steroid injection or surgery, traumatic or
neoplastic origin of symptoms, inability to fill in follow-
up forms or absence of self-determination in the partici-
pant. In participants with bilateral symptoms general
practitioners were instructed to include the hand with
the most severe complaints. After applying in- and
exclusion criteria, written informed consent was
obtained from participants by their general practitioner.
Interventions and injection technique
Participants received one or two intracarpal injections
with either 1 ml triamcinolonacetonide 10 mg/ml
(experimental intervention) or 1 ml NaCl 0.9% (control
intervention). One millilitre of either TCA or NaCl was
injected just to the ulnar side of the palmaris longus
tendon, proximal to the wrist crease. The needle was
aimed toward the carpal tunnel at a 10- to 20-degree
angle of entry. If there were no paresthesias during
insertion of the needle, the trial solution was injected[1].
All general practitioners involved in the study were
offered a two-hour course on the technique of injection
therapy, using an arm phantom for instruction.
Randomisation and allocation concealment
For the randomisation procedure an electronic online
randomization tool developed by G. Urbaniak (http://
www.randomizer.org, accessed on 22.12.2002) was used.
Block randomisation was realised by creating 7 sets of
blocks of 10 random numbers. Even numbers corre-
sponded with active trial medication and uneven num-
bers with placebo to ensure equal numbers of allocation
to active and placebo treatment. Treatment allocation
was written on a paper and enclosed in an opaque and
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assistant at a remote location (who was not involved in
the study) was contacted, who then drew an envelope
and sent the allocated trial medication to the injecting
general practitioner.
Study design, blinding and bail out treatment
Every patient with typical signs and symptoms of carpal
tunnel syndrome presenting to one of the participating
general practitioners was asked to participate in the
trial. As an aid in establishing the diagnosis of carpal
tunnel syndrome a list of clinical criteria for CTS of the
American Academy of Neurologists and a modified ver-
sion of a hand diagram developed by Katz et al. were
provided[7,12]. After applying inclusion and exclusion
criteria, assessment of baseline clinical characteristics
took place by the patient’s own general practitioner,
who also performed the blinded assessment of the
short-term follow-up two weeks after the intervention.
In order to guarantee blinding of short-term outcome
assessment (after randomisation) the trial medication
was injected one week after inclusion by another inde-
pendent general practitioner. If the result of the first
injection was not satisfactory in the participant’so p i -
nion, the participants were given a second injection by
the other independent general practitioner one week
later. One week after the last injection with the trial
medication the participants were instructed to return to
their own general practitioner for assessment of short-
term outcomes. Because a placebo look-alike of the
triamcinolonacetonide injection suspension could not be
manufactured, blinding was realised by applying the
injection while the participant was blindfolded.
Bailout treatment
If during short term outcome assessment the response
to the blinded injection(s) was insufficient according to
agreement between the patient and general practitioner,
blinding was discontinued and the trial centre was asked
whether injected trial medication consisted the active
substance (TCA) or control treatment (NaCl). Partici-
pants who were randomized to TCA with no response
to blinded injections were referred to secondary care for
operative treatment and not included in the long-term
analysis.
In case of insufficient response after injection of NaCl,
one or two additional injections with TCA (bail-out
treatment) with weekly intervals were given without
blinding. In case of insufficient response to one or two
bailout injections, participants were referred to second-
ary care for operative treatment and not included in the
long-term follow-up analysis. Introducing bailout treat-
ment for non-responders to NaCl was required, as the
medical ethics committee considered it to be unethical
to leave patients, who received placebo treatment with
no improvement in symptoms after intervention,
untreated.
Outcomes measurements
Baseline assessment consisted of recording of demo-
graphic and disease-specific characteristics of partici-
pants to identify differences in prognostic indicators
between the two intervention groups.
During short-term assessment the following primary
outcome measurements were recorded:
1. Direct treatment response (based on consensus
between physician and patient):
￿ 0 = no response
￿ 1 = partial response, but not satisfactory, warrant-
ing further treatment
￿ 2 = partial response, satisfactory, not warranting
further treatment
￿ 3 = complete resolution of symptoms and signs
2. Improvement as perceived by patient:
￿ -2 = much worse
￿ -1 = worse
￿ 0 = not better/not worse
￿ + 1 = better
￿ + 2 = much better
3. Symptom severity was assessed by using the Symp-
tom Severity Scale (SSS) and functional disability by
using the Functional Status Scale (FSS), which are both
part of the Boston Carpal Tunnel Questionnaire
(BCTQ). The BCTQ is a patient-reported outcome mea-
sure for CTS and has been tested for validity, reliability
and responsiveness. Psychometric properties of the
BCTQ have been described extensively elsewhere[13].
The SSS has 11 questions, the FSS 8 questions and both
use a five-point scale. Each scale generates a final score
(sum of individual item scores divided by number of
items), which ranges from 1 to 5. Higher SSS and FSS
scores correlate with more severe symptoms and func-
tional impairment respectively.
4. proportion of participants with recurrences requir-
ing repeat TCA-injections or referral to secondary care
for operative treatment during the follow-up period of
12 months.
5. The secondary outcomes of side effects and adverse
events were systematically recorded (qualitatively and
quantitatively) at short-term assessment and during fol-
low-up.
Follow up measurements were performed by sending
questionnaires to participants 1, 3, 6 and 12 months
after the last injection and consisted of the same
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except for direct treatment response.
Data regarding the number of recurrences (requiring
repeat steroid injection or referral to secondary care for
operative treatment) and handling of recurrences during
the follow-up phase were extracted from the electronic
health records of participants.
Sample size and data analysis
Calculations of sample size were based on a two-sided
alpha of 0.05, a statistical power of 0.90. The proportion
of participants treated with steroid injection with satis-
f a c t o r yr e s p o n s eo rc o m p l e t er e s o l u t i o no fs y m p t o m s
after two injections was expected to be at least 60%,
extrapolated from prior prospective studies[14,15]. Ade-
quate treatment response to placebo treatment was
expected to be 20%. Based on these calculations we
aimed to recruit 34 patients for each treatment group.
Analysis was planned according the intention to treat
principle. For continuous data the student T-test was
used if the distribution was normal and Mann-Witney
U test if there was not a normal distribution. For cate-
gorical data Fisher’se x a c tt e s tw a su s e d .F r i e d m a n n ’s
test was used to compare repeated observations on the
same subjects and to test if the distributions are the
same across repeated measures if a non-normal distribu-
tion of outcome data was suspected. Significance was
accepted at a probability value of < 0.05.
To calculate the Number Needed to Treat the formula
NNT = 1/ARR was used, where: ARR (Absolute Risk
Reduction) = CER (Control Group Event Rate) - EER
(Experimental Group Event Rate). The Event Rate was
the proportion of participants with a partial satisfactory
response, not warranting further treatment or complete
resolution of symptoms and signs for the outcome
direct treatment response.
Missing follow-up values were imputed based on the
available follow-up scores using the EM algorithm,
assuming that missing data occurred completely at ran-
dom (MCAR) [16]. Data were analysed using the statisti-
cal software SPSS version 14 (SPSS Inc Chicago, Illinois,
USA).
Results
During a period of 33 months (February 2003 to Octo-
ber 2005, follow-up finished in October 2006) 69 parti-
cipants who fulfilled the inclusion were recruited by 20
general practitioners in 20 general practices. At baseline
assessment the two groups were found to be comparable
regarding potentially prognostic indicators and differed
only in mean duration of symptoms. The median dura-
tion of symptoms was 13 weeks in the NaCl-group
(P25 =7 ,P 75 = 50) and 26 weeks in the TCA-group
(P25 =8 ,P 75 = 52) (see table 1). In 66 of the 69 (96%)
of the included patients the hand diagram was rated as
classical or probable CTS.
After randomisation 36 patients were allocated to
TCA and 33 to NaCl (one participant who was origin-
ally randomised to NaCl, was mistakenly allocated to
TCA).
Short-term efficacy
The results of primary outcomes one week after the last
injection as compared to baseline measurement are dis-
played in table 2. Three participants refused further par-
ticipation in the study after randomisation for unknown
reasons. Therefore they did not receive the allocated
intervention and were not analysed (figure 1).
11 participants received one blinded TCA injection
and 24 received two blinded TCA injections. Of the par-
ticipants that received one injection 10 responded to
treatment (91%) and of the 24 that received two injec-
tions 7 responded (30%).
The TCA-group showed better direct treatment
response (p = 0.013), perceived improvement (p = 0.01)
and more improvement than the NaCl-group in the out-
comes SSS BCTQ score (from 2.872 to 1.948 in the
TCA group versus from 2.815 to 2.529 in the NaCl
group) and FSS BCTQ score (from 2.456 to 1.881 in the
TCA group versus from 2.353 to 2.366 in the NaCl
group). The mean difference in change score was 0.637
(95% CI: 0.320, 0.960; p < 0.001) for the SSS BCTQ and
the mean difference in change score was 0.588 (95% CI:
0.232, 0.944; p = 0.02) for the FSS BCTQ. The Number
Needed to Treat to achieve satisfactory partial treatment
response or complete resolution of symptoms and signs
was 3 (95% CI: 1.83, 9.72).
Long-term efficacy
All non-responders to blinded intervention were
required to be treated with (non-blinded) TCA-injec-
tions and all non-responders to TCA (blinded and as
bail-out treatment) were referred to secondary care for
operative treatment. Therefore, it was decided to present
the long-term follow-up data of the effects of corticos-
teroid injections as a report of the cohort of patients
that had responded to treatment with TCA.
51% of the 69 included patients (35/69) entered the
follow-up period. 51% of these TCA-responders (18/35)
did not report any recurrences during follow-up and
49% of TCA-responders (17/35) had recurrences.
In the cohort that remained free of recurrences the
short term beneficial treatment effects of steroid injec-
tion(s) deteriorated during follow-up: main outcomes
BCTQ SSS (1.45, 1.55, 2.05 and 2.03 at resp. 1, 3, 6 and
12 months follow-up; p = 0.008) and BCTQ FSS (1.08,
1.19, 1.28 and 1.66 at resp. 1, 3, 6 and 12 months fol-
low-up; p = 0.012) increased during the entire follow-up
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ever they did not reach the pre-intervention levels (the
median score for the BCTQ SSS was 2.90 and for the
BCTQ FSS 2.50 at baseline for the participants treated
with TCA-injections).
In the TCA-responders that had recurrences 27 recur-
rences occurred in 17 participants. 9 participants had 1
recurrence, 6 participants 2 recurrences and 2 partici-
pants had 3 recurrences. 15o ft h e2 7r e c u r r e n c e s( 1 1
participants) were treated with steroid injection (7 parti-
cipants with one injection, 4 participants with 2 injec-
tions). None of the participants with recurrences were
treated with splinting. 12 (12 participants) of the 27
recurrences (17 participants) were referred to secondary
care for operative treatment.
Complications of treatment
There were no serious adverse events reported during
short-term and long-term assessment. The most fre-
quent reported side effects that had occurred within one
week after blinded interventions and bailout treatment
were steroid-flare (a delayed post injection transient
increase in pain which has been attributed to crystal-
induced synovitis): 14 events, hot flushes: 7 events, vaso-
vagal symptoms: 3 events and menstrual irregularities:
2 events.
Discussion
Summary of main findings
This is the first randomised controlled trial assessing
efficacy of steroid injections for carpal tunnel syndrome
in general practice.
Our results indicate that steroid injections applied by
trained general practitioners are effective regarding
short-term outcomes when compared to placebo injec-
t i o n s .T h ee f f e c ts i z ea ts h o r t - t e r m( o n ew e e ka f t e rl a s t
injection) assessment was substantial with a number
needed to treat of three to achieve satisfactory partial
treatment response or complete resolution of symptoms
and signs. The difference with placebo injections in
Table 1 baseline characteristics of study population
NaCl (n = 33) TCA(n = 36)
mean age (SD) 57.60 (40.30) 56,.5 (15.14)
sex (female/male) 26/7 27/9
median duration of symptoms (weeks) (P25, P75) 13 (7,50) 26 (8.52)
repetitive movements of hands 10/22 15/18
affected hand/arm (right/left) 21/9 18/14
dexterity (right/left) 32/0 31/3
quality of symptoms: a. dull aching discomfort arm/hand 25 28
b. weakness/clumsiness hand 22 23
c. paraesthesias hand 30 35
d. nocturnal complaints 28 32
e. presence of relieving factors 25 25
f. presence of provocative factors 30 31
score Katz hand diagram
classic 12 11
probable 19 22
unlikely 1 2
mean BCTQ symptom score (SD) 2.82 (0.79) 2.89 (0.78)
mean BCTQ functional score (SD) 2.35 (1.05) 2.48 (1.02)
comorbidity
diabetes 0 1
hypothyroidism 2 2
rheumatoid arthritis 1 1
pregnancy 0 1
NaCl = NaCl 0.9% (saline)
TCA = triamcinolonacetonide 1 mg/ml
BCTQ = Boston Carpal Tunnel Questionnaire
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and 0.588 for the FSS BCTQ. The mean scores of the
symptom and functional subscale of the Boston Carpal
Tunnel Questionnaire after steroid injection changed
positively with respectively 0.92 and 0.58. Both values
are higher than the threshold of 0.8 (SSS BCTQ) and
0.5 (FSS BCTQ) for clinical importance using patient
satisfaction as a criterion as determined by Leite et al
[13]. Although the TCA-group had a much longer dura-
tion of symptoms at baseline assessment, the short-term
outcomes were better.
Long-term effectiveness is less clear, since long-term
data were only available for the cohort of participants
who responded to TCA during the study and blinding
was discontinued if there was no response to the inter-
vention at short-term assessment.
Scores for BCTQ-SS and BCTQ-FSS deteriorated dur-
ing the follow-up period of 12 months, although they
did not reach pre-intervention levels.
Furthermore 17 (49%) of responders to TCA had
recurrences during the follow-up period of 12 months
and in this group 11 participants required treatment
with additional steroid injections and 12 ultimately had
to be referred to secondary care for operative treatment.
Comparison with existing literature
If we compare our results to findings of two high quality
randomised controlled studies performed in secondary
care by Dammers et al. and Armstrong et al. it appears
that response rate in our study is less (50% compared to
70% in study by Dammers and 70% in the study by
Armstrong), but duration of treatment response, recur-
rence rates and timing of recurrences were similar
[ 1 4 , 1 5 ] .T h es m a l l e rr e s p o n s er a t ec o u l dp a r t l yb e
explained by the type and dosage of steroid that was
used: Dammers et al used 40 mg of methylprednisolon
( w h i c hi sah i g h e rd o s a g eo fas t e r o i dw i t ht h es a m e
potency as triamcinolonacetonide, which was used
Table 2 short-term results after one or two injections of NaCl or TCA
NaCl TCA p-value
direct treatment response no response 17 9
partial response, not satisfactory 9 9
partial response, satisfactory 5 11
complete resolution of symptoms 0 6
0.013
mean score BCTQ 2.815 (0.795) 2.872(0.785)
symptom severity scale
before intervention (SD)
mean score BCTQ 2.529(0.847) 1.948(0.779)
symptom severity scale
after intervention (SD)
mean score BCTQ 2.353(1.045) 2.456(1.024)
functional status scale
before intervention (SD)
mean score BCTQ 2.366(1.0988) 1.881(0.810)
functional status scale
after intervention (SD)
change in mean score 0.286(0.554) 0.924(0.710) < 0.001
BCTQ symptom severity scale (SD)
change in mean score -0.135(0.557) 0.575(0.838) p = 0.002
BCTQ functional status scale (SD)
patient perceived improvement much worse 1 0
worse 2 1
not better not worse 17 9
better 10 9
much better 2 15
0.01
NaCl = NaCl 0.9% (saline)
TCA = triamcinolonacetonide 1 mg/ml
BCTQ = Boston Carpal Tunnel Questionnaire
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Page 6 of 11Figure 1 flow of patients during intervention phase
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more potent steroid than triamcinolonacetonide). A sec-
ond explanation could be the fact that we used rigorous
allocation concealment and randomisation procedures,
since bias due to inadequate allocation concealment and
randomisation can lead to overestimation of treatment
effects. Thirdly it could have been possible that in less
clear-cut cases the diagnosis of carpal tunnel syndrome
was not certain and therefore steroid injection were less
effective (although the scores of the Katz-hand diagram
suggest that general practitioners can diagnose carpal
tunnel syndrome reliably on clinical grounds). A final
possible explanation for the smaller response rate to
steroid injections in our study could be the long dura-
tion of symptoms at baseline for the steroid-group in
our study (76 weeks) as compared to the study by Dam-
mers (32 weeks) and Armstrong (39% of the steroid
group had symptoms for less than one year).
Strengths and the limitations of this study
Strong points in our study were that randomisation,
allocation concealment and blinding procedures were
rigorous (with blinding of patient and outcome asses-
sors) and that with the Boston Carpal Tunnel Question-
naire we used a valid and reliable patient-based
outcome measurement tool.
Figure 2 BCTQ symptom score of responders to TCA during follow-up
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Page 8 of 11Figure 3 BCTQ functional score of responders to TCA during follow-up
Table 3 long-term results of responders to tca that did not have recurrences during follow-up
Follow-up
1 month 3 months 6 months 12 months p-value
1
Median score BCTQ symptom severity scale(min, max) 1.45 1.55 2.05 2.03
(0.99, 2.90) (1.00, 4.10) (1.00, 3.49) (1.09, 5.18) 0.008
N=1 8 N=1 8 N=1 8 N=1 8
Median score BCTQ functional status scale (min, max) 1.08 1.19 1.28 1.66
(0.93, 2.99) (0.91, 3.38) (1.00, 3.16) (1.00, 4.53) 0.012
N=1 8 N=1 8 N=1 8 N=1 8
1. Friedman test
BCTQ = Boston Carpal Tunnel Questionnaire
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might have been that our study consisted of milder
c a s e st h a np r e v i o u ss t u d i e s ,w h i c ho n l ys t u d i e ds e c o n d -
ary care patient populations.
Our trial protocol did not include any nerve conduc-
tion studies, because the aim of our study was to investi-
gate effectiveness of steroid injection for participants
with a clinical diagnosis of CTS as established by a gen-
eral practitioner. Nevertheless, the clinical characteristics
and results of hand diagram scores of participants (table
1) show that a large proportion (96%) of our study popu-
lation had typical features of CTS and that therefore gen-
eral practitioners seem to identify classical cases of CTS
reliably. Although practice guidelines for CTS suggest
that Nerve Conduction Studies (NCS) are important to
establish the diagnosis of CTS, NCS are a controversial
i s s u es i n c et h e r ei sn og o l dd i a g n o s t i cs t a n d a r df o rC T S
and NCS have shown to have certain limitations (mainly
lack of sensitivity and standardized protocols) and corre-
lations between NCS and clinical outcome measures are
weak to moderate, a phenomenon also known as the
“clinical-neurophysiologic paradox” [2,7,17].
Due to the decision of the medical ethics committee
we had to discontinue blinding in our study if there was
no response to trial intervention at short-term assess-
ment, since it was considered unethical to leave patients
with symptoms of carpal tunnel syndrome untreated
during the follow-up period of one year. One could
argue that introduction of bailout treatment for placebo
non-responders has led to less robust long-term data
and this therefore on the other hand would justify from
an ethical perspective a randomised controlled trial
(with a follow-up period of one year) without the use
escape-treatment for non-responders to placebo-treat-
ment. Two other randomised controlled trials that
investigated efficacy of steroid injections for CTS in sec-
ondary care were faced with the same dilemma [14,15].
Implications for future research or clinical practice
In our opinion steroid injection into the carpal tunnel is
a safe, easy to learn and to apply and a relatively inex-
pensive therapeutic intervention. Also response to ster-
oid injection could be helpful in establishing the
diagnosis of carpal tunnel syndrome. Our study indi-
cates that general practitioners can reliably identify
patients with carpal tunnel syndrome using symptoms,
signs and a self-administered hand diagram.
Although our study has certain limitations, the design
and setting of our study leads to conclusions that are
generizable for the population of patients presenting to
their general practitioner with a clinical diagnosis of car-
pal tunnel syndrome. Therefore we feel that initial treat-
ment by general practitioners with steroid injections in
cases of CTS with a typical history and without thenar
wasting is justified. If there is no response after two
injections or if recurrences occur, nerve conduction stu-
dies may be warranted before surgical therapy is
considered.
Although we observed only a few minor side effects
and no adverse events occurred in our study, studies
addressing safety of corticosteroid injections for CTS
provided by general practitioners using larger sample
sizes are needed.
Conclusions
The results of our study suggest that in patients present-
ing to their general practitioner with a clinical diagnosis
of CTS intra-carpal injection with one or two injections
with 1 ml triamcinolonacetonide 10 mg/ml is effective
with respect to short-term outcomes when compared to
placebo-injections.
Long-term effectiveness is less clear: the achieved
treatment effects seem to diminish slowly in half of the
cohort of patients that responded to steroid injections
during the 12 months after the intervention and recur-
rences occurred in the other half of the cohort of ster-
oid responders.
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